NLRP3 and neoplasm: The failure of DNA methyltransferase inhibitors to re‐establish NLRP3 expression in our epigenetic drug screen, combined with database evidence showing hypomethylation at the NLRP3 promoter region in tumours (Figure S5C), suggests that DNA methylation is not accountable for the transcriptional silencing of NLRP3.